Under Eric's leadership, InnerWorkings and Echo Global Logistics went public, and he played a key role in MediaBank's $1.5 billion merger, which garnered significant media attention. Eric also funded ThePoint.comwith $1 million, which later transformed into Groupon, a global tech success. His most successful venture to date is Tempus, which aims to bring data-driven hope to cancer care. For Eric, disruption isn't just a job; it's part of his nature.
Tempus AI has initiated a series of important AI opportunities to advance precision medicine and improve patient care utilizing :
: It is an AI-powered oncology target discovery and validation platform that integrates real-world patient data, human-derived biological models, and CRISPR screens to identify and validate new drug targets quickly. This accelerates drug discovery timelines while providing valuable clinical relevance by aligning patient data to patient-derived organoids (PDOs).
Precision Meets AI: Tempus AI is expanding its care platform, , to include breast cancer, utilizing AI to analyze patient data, identify gaps in treatment, and provide real-time and guideline-based recommendations that will assist physicians to provide faster, smarter, and more individualized cancer care at scale.
Tempus and Boehringer: Tempus AI has partnered with in the multi-year venture for the advancement of cancer research. It is the collaboration that uses real-world patient data together with advanced analytics to help drug discovery, and ultimately to facilitate more refined, life-saving cancer treatments.
Tempus and AstraZeneca: Tempus AI with $200 million foundation model partnership with AstraZeneca and Pathos is advancing the future of oncology. Tempus is merging expansive clinical data sets with to accelerate diagnosis, reshape drug discovery, and develop truly personalized cancer therapies.
Integrating Multimodal Data: Tempus AI's Fuses program is redefining precision care by integrating rich with advanced AI models. It accelerates theranostics, uncovers patterns of drug resistance, and delivers predictive diagnostics, bringing truly personalized data-informed decisions closer to real-world clinical practice.
Tempus and Illumina: are transforming healthcare by creating precision medicine solutions that leverage AI and genomic science. Leveraging multimodal data, their partnership trains advanced algorithms to make molecular profiling a standard across cancer, cardiology, neurology, and many more.
GSK and Tempus: Tempus AI to enhance drug discovery using its powerful AI platform and one of the world's largest de-identified patient datasets. The partnership enhances trial design, accelerates recruitment, and unlocks transformational treatments in precision medicine.
AI Olivia: Tempus AI introduced Olivia, a cutting-edge concierge app powered by AI. By unifying health records, device data, and clinical insights, Olivia helps patients take charge of their care with clarity, confidence, and real-time, personalized guidance.
